Genetic Modulation at the Neural Microelectrode Interface: Methods and Applications

Bailey M WinterErin K Purcell


The use of implanted microelectrode arrays (MEAs), in the brain, has enabled a greater understanding of neural function, and new treatments for neurodegenerative diseases and psychiatric disorders. Glial encapsulation of the device and the loss of neurons at the device-tissue interface are widely believed to reduce recording quality and limit the functional device-lifetime. The integration of microfluidic channels within MEAs enables the perturbation of the cellular pathways, through defined vector delivery. This provides new approaches to shed light on the underlying mechanisms of the reactive response and its contribution to device performance. In chronic settings, however, tissue ingrowth and biofouling can obstruct or damage the channel, preventing vector delivery. In this study, we describe methods of delivering vectors through chronically implanted, single-shank, "Michigan"-style microfluidic devices, 1⁻3 weeks, post-implantation. We explored and validated three different approaches for modifying gene expression at the device-tissue interface: viral-mediated overexpression, siRNA-enabled knockdown, and cre-dependent conditional expression. We observed a successful delivery of the vectors along the length of the MEA, where...Continue Reading


Jan 20, 2004·The Journal of Clinical Psychiatry·Paul E GreenbergPatricia K Corey-Lisle
Aug 18, 2004·Journal of Neurosurgery·Zhi-Jian ChenPanos P Fatouros
Jul 25, 2006·Trends in Neurosciences·Mikhail A Lebedev, Miguel A L Nicolelis
Apr 6, 2007·Journal of Neural Engineering·R L RennakerD A Wilson
May 23, 2007·Biomaterials·John P Seymour, Daryl R Kipke
Dec 26, 2008·Journal of Neurophysiology·Kip A LudwigDaryl R Kipke
Jun 30, 2009·Journal of Neuroscience Methods·Erin K PurcellDaryl R Kipke
Apr 29, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kevin N HascupJan Kehr
Oct 7, 2011·Nature·Joseph E O'DohertyMiguel A L Nicolelis
Dec 6, 2011·Nature Neuroscience·Polina AnikeevaKarl Deisseroth
Jan 12, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Anders WimoAlzheimer Disease International
Feb 22, 2013·Journal of Medical Economics·Gabriel AdelmanKathleen F Villa
Feb 26, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Stacey L KowalAnjali Jain
Jul 31, 2013·Biomaterials·Lohitash KarumbaiahRavi V Bellamkonda
Jan 11, 2014·Current Biology : CB·Joshua H Jennings, Garret D Stuber
Dec 3, 2014·Journal of Neural Engineering·Mehdi JorfiJeffrey R Capadona
Dec 23, 2014·Current Opinion in Solid State & Materials Science·Salah SommakiaKevin J Otto
Dec 30, 2014·ACS Chemical Neuroscience·Takashi D Y KozaiXinyan Tracy Cui
Aug 12, 2016·Nature Communications·Karissa C ArthurBryan J Traynor
Mar 31, 2017·Journal of Neurophysiology·Joseph W SalatinoErin K Purcell
Feb 8, 2018·Nature Communications·Youssef EzzyatMichael J Kahana
Feb 23, 2018·Biomaterials·Hillary W BedellJeffrey R Capadona
Feb 27, 2018·Biomaterials·Cassie BennettAbhishek Prasad
May 29, 2018·Advanced Functional Materials·Steven M WellmanTakashi D Y Kozai
Jul 28, 2018·Biomaterials·Asiyeh GolabchiXinyan Tracy Cui
Dec 7, 2018·Nature Biomedical Engineering·Joseph W SalatinoErin K Purcell
Feb 1, 2017·Nature Reviews. Materials·Ritchie ChenPolina Anikeeva


May 22, 2019·Nature Biomedical Engineering·Laura CabreraErin K Purcell
Jul 25, 2019·Micromachines·Joseph J Pancrazio, Stuart Cogan

Methods Mentioned

genetic modification

Related Concepts

Related Feeds

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.